FQ1:2011 Results; Impella Utilization Growth Continues
Wedbush predicts continued organic growth will drive Abiomed to profitability. Report ranks Abiomed among a small group of cardiac device companies demonstrating consistent and sustainable growth.
2010 08-04 Abiomed continues to penetrate the market – _FQ1 Earnings